5-(N,N-dimethyl)-Amiloride Hydrochloride: Selective NHE1 Inhibitor for pH and Cardiovascular Research

Executive Summary: 5-(N,N-dimethyl)-Amiloride (hydrochloride) is a crystalline NHE1 inhibitor with submicromolar potency, highly selective for Na+/H+ exchanger isoforms NHE1, NHE2, and NHE3 (Ki: 0.02 µM, 0.25 µM, 14 µM, respectively) [APExBIO]. This compound blocks sodium influx and proton extrusion, disrupting intracellular pH regulation and sodium balance in mammalian cells. It is demonstrated to protect against ischemia-reperfusion injury in cardiac tissue by normalizing sodium levels and preventing contractile dysfunction [Chen et al., 2021]. DMA also inhibits ouabain-sensitive ATPase activity in hepatic membranes and reduces alanine uptake, implicating broad roles in ion transport and cellular metabolism. Usage parameters and solubility information are critical for experimental reproducibility and are detailed below.

Biological Rationale

Maintenance of intracellular pH and sodium homeostasis is essential for cell viability, especially in excitable tissues like heart and endothelium. The Na+/H+ exchanger (NHE) family mediates the antiport of intracellular H+ for extracellular Na+, directly controlling cytosolic pH and cell volume. NHE1, the predominant isoform in the heart and vasculature, is implicated in cell response to ischemic, hypoxic, and inflammatory insults [Chen et al., 2021]. Overactivation of NHE1 leads to sodium and calcium overload, metabolic derangements, and cell death during reperfusion. Selective inhibition of NHE1 and related isoforms is therefore a validated strategy for probing or modulating cardiovascular and metabolic disease pathways. 5-(N,N-dimethyl)-Amiloride hydrochloride (DMA) provides high selectivity and potency, enabling precise inhibition of NHE1/2/3 with minimal off-target effects on other NHE family members [APExBIO].

Mechanism of Action of 5-(N,N-dimethyl)-Amiloride (hydrochloride)

DMA is a synthetic derivative of amiloride, structurally modified for enhanced NHE1 affinity. It binds to the extracellular face of Na+/H+ exchangers, competitively inhibiting sodium-proton exchange. Inhibition constants (Ki) are 0.02 µM (NHE1), 0.25 µM (NHE2), and 14 µM (NHE3), with negligible activity on NHE4, NHE5, and NHE7 at concentrations ≤10 µM [APExBIO]. This selectivity profile distinguishes DMA from parent amiloride and other analogs. Mechanistically, DMA blockade of NHE1 halts proton extrusion and sodium entry, leading to cytosolic acidification and reduced sodium load. In cardiac and endothelial cells, this action prevents sodium-driven calcium overload and subsequent contractile or permeability dysfunction [Chen et al., 2021]. DMA also inhibits ouabain-sensitive ATP hydrolysis and Na+/K+-ATPase in hepatocyte membranes, and reduces alanine uptake, linking it to broader ion transport and metabolic regulation.

Evidence & Benchmarks

• DMA inhibits NHE1 with a Ki of 0.02 µM, NHE2 at 0.25 µM, and NHE3 at 14 µM, offering high isoform selectivity (APExBIO, product sheet).
• DMA effectively blocks Na+/H+ exchange-mediated sodium influx and proton extrusion in cardiac and endothelial cells (Chen et al., 2021, DOI).
• DMA administration protects cardiac tissue from ischemia-reperfusion injury, reducing tissue sodium levels and preserving contractile function (Chen et al., 2021, DOI).
• DMA inhibits ouabain-sensitive ATP hydrolysis and Na+/K+-ATPase in rat liver plasma membranes, and decreases alanine uptake in hepatocytes (APExBIO, product sheet).
• DMA is soluble up to 30 mg/ml in DMSO and dimethylformamide, but not recommended for long-term solution storage; stock solutions should be used promptly (APExBIO, product sheet).

Applications, Limits & Misconceptions

DMA is widely utilized in research on intracellular pH regulation, Na+/H+ exchanger signaling, and cardiovascular disease models. Key applications include:

• Acute inhibition of NHE1-mediated sodium and pH regulation in cardiac ischemia-reperfusion models.
• Assessment of sodium-driven cytosolic acidification processes in endothelial injury and vascular permeability [Chen et al., 2021].
• Dissection of Na+/K+-ATPase-dependent and -independent transport processes in hepatocytes.
• Tool compound for benchmarking new NHE inhibitors or mechanistic studies in translational cardiovascular research.

For a comprehensive mechanistic overview of DMA in translational and cardiac research, see "5-(N,N-dimethyl)-Amiloride Hydrochloride: Decoding Na+/H+...", which this article extends by detailing isoform selectivity and metabolic effects. For advanced NHE1 signaling studies in real-world models, "Advanced NHE1 Inhibition Protocols" is complemented here by new storage and solubility parameters. To understand DMA's impact in endothelial injury, "Unraveling Na+/H+ Exchanger Function" discusses related biomarker strategies, while this article provides updated evidence on contractile protection and hepatic effects.

Common Pitfalls or Misconceptions

• DMA is not recommended for diagnostic or therapeutic use in humans; it is for research use only (APExBIO).
• It does not significantly inhibit NHE4, NHE5, or NHE7 at concentrations ≤10 µM; use higher concentrations only with caution.
• Long-term solution storage (>1 week) is not advised due to potential degradation; prepare fresh aliquots for each experiment.
• DMA may inhibit Na+/K+-ATPase at higher concentrations, complicating interpretations in non-cardiac tissues.
• Its effects are context-dependent; not all cell types express sufficient NHE1/2/3 for robust inhibition effects.

Workflow Integration & Parameters

For optimal results, DMA should be dissolved at up to 30 mg/ml in DMSO or dimethylformamide. Aliquots are stored at -20°C and protected from light. Working solutions should be freshly prepared and used within the same day. Typical experimental concentrations range from 0.01 µM (for selective NHE1 inhibition) to 10 µM (for broader NHE2/3 coverage). Controls should include vehicle only and, where relevant, alternative NHE inhibitors to validate selectivity. Result interpretation must consider DMA’s possible effect on Na+/K+-ATPase and other transporters at supraphysiological doses. APExBIO, as the provider of the C3505 kit, recommends strict cold-chain management and prompt usage of solutions (specifications).

Conclusion & Outlook

5-(N,N-dimethyl)-Amiloride hydrochloride (DMA) is a potent, selective Na+/H+ exchanger inhibitor enabling precise investigation of intracellular pH and sodium signaling in cardiovascular and metabolic research. Its well-characterized selectivity profile and protective effects in ischemia-reperfusion and endothelial injury models position DMA as a reference tool in translational workflows. Appropriate handling, concentration selection, and experimental controls are essential for robust, interpretable results. Future innovations may expand DMA’s applications into biomarker-driven screening and combinatorial therapeutic research. For detailed product information, refer to the 5-(N,N-dimethyl)-Amiloride (hydrochloride) product page.